p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis
Ming Jiang
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorCorresponding Author
Zhi-Ming Shao
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, 399 Ling-Ling Road, Shanghai Medical University, Shanghai, 200032, People's Republic of China. Fax: 86-21-64174774Search for more papers by this authorJun Wu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJing-Song Lu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorLi-Ming Yu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJian-Da Yuan
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorQi-Xia Han
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorZhen-Zhou Shen
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJoseph A. Fontana
University of Maryland Cancer Center, University of Maryland at Baltimore, Baltimore, Maryland
Search for more papers by this authorMing Jiang
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorCorresponding Author
Zhi-Ming Shao
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, 399 Ling-Ling Road, Shanghai Medical University, Shanghai, 200032, People's Republic of China. Fax: 86-21-64174774Search for more papers by this authorJun Wu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJing-Song Lu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorLi-Ming Yu
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJian-Da Yuan
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorQi-Xia Han
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorZhen-Zhou Shen
Department of Surgery, Molecular Biology Laboratory, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
Search for more papers by this authorJoseph A. Fontana
University of Maryland Cancer Center, University of Maryland at Baltimore, Baltimore, Maryland
Search for more papers by this authorAbstract
p21/waf1/cip1 and mdm-2 are downstream effectors of p53. p21 plays a major role in negatively regulating cell-cycle progression, while mdm-2 inhibits p53 effects, and its role has been implicated in oncogenesis. In this study, we investigated the expression profiles of p21, mdm-2 and p53 in human breast-carcinoma tissues. The aim was to determine whether a correlation exists between the expression profiles of these markers and tumor differentiation, ER status and prognosis. We studied tumor specimens obtained from 106 patients and found a highly significant association among low histology grade, p53 over-expression, high mdm-2 expression and lack of p21 expression. Our studies also demonstrate that, in human breast cancer, low levels of p21 and higher mdm-2 levels directly correlate with the onset of lymph-node metastases and shortened patient survival. Furthermore, the expression profiles of p21, mdm-2 and p53 were independently correlated with patient survival. Int. J. Cancer 74:529–534, 1997. © 1997 Wiley-Liss, Inc.
References
- Barbareschi, M., Caffo, O., Doglioni, C., Fina, P., Marchetti, A., Buttitta, F., Leek, R., Morelli, L., Leonard, E., Bevilacqua, G., Dalla Palma, P. and Harris, A. L., p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen-receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Brit. J. Cancer, 74, 208–215 (1996a).
- Barbareschi, M., Doglioni, C., Veronese, S., Bonzanini, M., Dalla Palma, P., Harris, A. L. and Caffo, O., p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. Europ. J. Cancer, 32, 2182–2183 (1996b).
- Bueso-Ramos, C., Manshouri, T., Haidar, M., Yang, Y., McCown, P., Ordonez, N., Glassman, A., Sneige, N. and Albitar, M., Abnormal expression of MDM-2 in breast carcinoma. Breast Cancer Res. Treat., 37, 179–188 (1996).
-
Bukholm, I. K.,
Nesland, J. M.,
Karlsen, R.,
Jacobsen, U. and
Borresen, A. L.,
Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.
J. Pathol.,
181,
140–145
(1997).
10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J. Jr., Vogelstein, B. and Kastan, M. B., Interaction between p53 and MDM2 in a mammalian cell-cycle checkpoint pathway. Proc. nat. Acad. Sci. (Wash.), 91, 2684–2688 (1994).
- Chen, Y.-Q., Cipriano, S. C., Arenkiel, J. M. and Miller, F. R., Tumor suppression by p21WAF1. Cancer Res., 55, 4536–4539 (1995).
- Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y. and Wang, X. F., Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. nat. Acad. Sci. (Wash.), 92, 5545–5549 (1995).
-
Doglioni, C.,
Pelosio, P.,
Laurino, L.,
Macri, E.,
Meggiolaro, E.,
Favretti, F. and
Barbareschi, M.,
p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation.
J. Pathol.,
179,
248–253
(1996).
10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, L. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817–825 (1993).
- El-Deiry, W. S., Tokino, T. and Waldman, T., Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910–2919 (1995).
- Elston, C. W. and Ellis, I. O., Pathological prognostic factors in breast cancer, the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19, 403–410 (1991).
- Encoh, T. and Norbury, C., Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends biol. Sci., 20, 426–430 (1995).
- Haley, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D. and Lassar, A. B., Correlation of terminal cell-cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 1018–1024 (1995).
- Hartwell, L. and Kastan, M. B., Cell-cycle control and cancer. Science, 266, 1820–1828 (1994).
- Hunt, T. and Nasmyth, K., Dams and sluices. Nature (Lond.), 366, 634–635 (1993).
- Jiang, H., Lin, J., Su, Z. Z., Collart, F. R., Huberman, E. and Fisher, P. B., Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9, 3397–3406 (1994).
- Johnson, E. A., Davidson, A. G., Hostetter, R. B., Cook, L. L., Thomas, E. M. and Quinlan, D. C., The expression of WAF-1 in node-negative infiltrating ductal breast carcinoma. Proc. Amer. Ass. Cancer Res., 37, 569a (1996).
- Kute, T. E., Shao, Z-M., Sugg, N. K., Long, R. T., Russel, G. B. and Case, L. D., Cathepsin-D as a prognostic indicator for node-negative breast-cancer patients using both immunoassays and enzymatic assays. Cancer Res., 50, 4901–4909 (1992).
- Li, X. S., Rishi, A. K., Shao, Z. M., Dawson, M. I., Jong, L., Shroot, B., Reichert, U., Ordonez, J. and Fontana, J. A., Post-transcriptional regulation of p21 WAF1/CIP1 expression in human breast-carcinoma cells. Cancer Res., 56, 5055–5062 (1996).
- Li, Y., Laurent-Puig, P., Salmon, R. J., Thomas, G. and Hamelin, R., Polymorphism and probable lack of mutation in the WAF1/CIP1 gene in colorectal cancer. Oncogene, 10, 599–601 (1995).
- Marchetti, A., Buttitta, F., Girlandos, Dalla Palma, P., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G. and Barbareschi, M., mdm2-gene alteration and mdm2 protein expression in breast carcinomas. J. Pathol., 175, 31–38 (1995a).
- Marchetti, A., Buttitta, F., Pellegrini, S., Lori, A., Bertacca, G. and Bevilacqua, G., Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinoma: a polymorphism at codon 31. Int. J. Oncol., 6, 187–189 (1995b).
- Marchetti, A., Doglioni, C. and Barbareschi, M., p21 mRNA and protein expression in non-small-cell lung cancer: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12, 1319–1324 (1996).
- Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E. and Givol, D., Induction of WAF1/CIP1 by p53-independent pathway. Cancer Res., 54, 3391–3395 (1994).
- Oliner, J. D., Kinzler, K. W. and Metlzer, P. S., Amplification of gene encoding 1 p53-associated protein in human sarcomas. Nature (Lond.), 358, 80–83 (1992).
- Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, W. K. and Vogelstein, B., Oncoprotein MDM2 conceals the activation domain of suppressor p53. Nature (Lond.), 362, 857–860 (1993).
- Shao, Z-M., Dawson, M. I., Li, X., Rishi, A. K., Sheikh, M. S., Han, Q. X., Ordonez, J. V., Shroot, B. and Fontana, J. A., p53-independent G1/G0 arrest and apoptosis induced by a novel retinoid in human breast-cancer cells. Oncogene, 11, 493–504 (1995).
- Sheikh, M. S., Shao, Z-M., Hussain, H. and Fontana, J. A., The p53-binding protein MDM2 is differentially expressed in human breast carcinoma. Cancer Res., 53, 3226–3228 (1993).
- Tron, V. A., Tren, L., Yong, W. P. and Trotter, M. J., Differentiation-associated over-expression of the cyclin-dependent kinase inhibitor p21WAF-1 in human cutaneous squamous-cell carcinoma. Amer. J. Pathol., 149, 1139–1146 (1996).
- Xiong, Y., Hannon, G. I., Zhang, H., Casso, D., Kobayashi, R. and Beach, D., p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366, 701–707 (1993).
- Zambetti, G. P. and Levine, A. J., A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7, 855–865 (1993).
- Zhang, W., Grasso, L., McClain, C. D., Gambrel, A. M., Cha, Y., Travali, S., Deisseroth, A. B. and Mercer, W. E., p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668–674 (1995a).
- Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., Claxton, D. and Deisseroth, A. B., High levels of constitutive WAF1/CIP1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1, 1051–1057 (1995b).
Citing Literature
